. From 1990 to 1998, the prevalence of DM in the United States rose by an estimated 33% (Mokdad, 1998) . Type 2 DM, a disease normally associated with older adults, has become increasingly common in children, adolescents, and young adults during the previous decade (Pinhas-Hamiel, 1996; Rosenbloom, 1999) .
Despite major treatment advances, DM remains a chronic disease associated with several debilitating microvascular (e.g., retinopathy, neuropathy, nephropathy) and macrovascular (e.g., cardiovascular disease [CVD] , peripheral vascular disease) complications. Fifty percent of individuals with DM will eventually die of CVD (Grundy, 1999) .
CLASSIFICATION OF DIABETES AND OTHER FORMS OF GLUCOSE INTOLERANCE
In 1997, the American Diabetes Association (ADA) introduced new diagnostic and classification criteria for DM and other forms of glucose intolerance (American Diabetes Association, 1997). The system includes the following four clinical classifications of DM:
• Type 1 DM.
• Type 2 DM.
• Other specific types of diabetes (e.g., secondary to other causes).
• Gestational diabetes mellitus (GDM).
The two categories of glucose intolerance include impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). Type 1 DM is primarily associated with an autoimmune destruction of the insulin producing pancreatic beta cells-whereas type 2 DM is associated with insulin resistance and impairments in insulin secretion. This classification is based on an etiologic classification of DM and replaces the more phenotypical classification system that categorized clients as insulin dependent DM (IDDM) and non-insulin dependent DM (NIDDM) categories (National Diabetes Data Group, 1979) . In addition, age and gender standardized rates of undiagnosed DM for non-Hispanic White individuals, non-Hispanic Black individuals, and Mexican Americans 20 years and older were 2.5%, 3.6%, and 4.5%, respectively. Because 90% of all DM is Type 2, these figures represent the growing numbers and ethnic disparities in the development of Type 2 OM. Among the other primary risk factors are family history, obesity, and physical inactivity (Harris, 1998) .
RISK FACTORS IN THE DEVELOPMENT OF TYPE 2 DIABETES

DIAGNOSTIC CRITERIA FOR DIABETES
The diagnosis of DM can be made from any three of the following criteria:
• Symptoms of diabetes plus casual plasma blood glucose concentration greater than 200 mg/dL. Casual is defined as any time of day or night without regard to the time since the previous meal.
• Fasting plasma glucose greater than 126 mg/dL. Fasting is defined as no caloric intake for at least 8 hours.
• Two hour plasma glucose greater than 200 mg/dL during an oral glucose tolerance test (OGTT). The OGTT should be performed using a glucose load containing the equivalent of 75 grams of anhydrous glucose dissolved in water.
In the absence of hyperglycemia with acute metabolic decompensation, these criteria should be confirmed by repeat testing on a different day. The OGTT is not recommended for routine use. However, in clients with a clear history of hyperglycemia which is not captured in the fasting state, such as Mr. J, the OGTT may be of value.
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Clinical Rounds: NP Link It can be noted that each of the individuals in the previous scenarios meets the criteria for OM. None of the individuals have a history of diabetic ketoacidosis (DKA), and have had an extended period of glucose intolerance. This suggests an absolute loss of circulating insulin, as is seen in Type 1 DM, did not occur. Thus, their phenotypic expression is consistent with Type 2 DM.
PHILOSOPHY OF DIABETES TREATMENT AND MANAGEMENT
Multiple changes in DM treatment and management have occurred during the past two decades. These changes have been influenced by the striking results of the Diabetes Control and Complications Trial (DCCT) for Type l OM (DCCT Research Group, 1993) , and the United Kingdom Prospective Diabetes Study (UKPDS) for Type 2 DM (UKPDS, 1998). The results of these two landmark studies support the theory that the microvascular complications of DM can be prevented or delayed through the maintenance of normoglycemia.
These studies also provide evidence that the macrovascular complications of DM likely result from the interaction of hyperglycemia, hypertension, and dyslipidemias. Therefore, the current focus of DM therapy involves aggressive therapy for normalization of blood glucose, blood pressure, and lipids for the prevention of CVD.
GENERAL TREATMENTS FOR DIABETES
Prior to 1995, only two pharmacological options (i.e., insulin,. sulfonylureas) were available in the United States to treat hyperglycemia in clients with Type 2 DM. The introduction of four new classes of medications (i.e., biguanides, thiazolidinediones, meglitinides, a-glucosidase inhibitors) and insulin analogs (e.g., Jispro) into the U.S. market have revolutionized the treatment of Type 2 DM.
These medications can be used alone or in combination to modify the primary physiologic abnormalities of Type 2 DM (i.e., decreased insulin secretion, insulin resistance, decreased suppression of hepatic glucose production). However, the introduction of these medications has increased the complexity of pharmacological regimens used to treat Type 2 DM as health care providers attempt to determine the best combination of diabetes medications and dosages needed to achieve normoglycemia.
It is beyond the scope of this column to review the diet and exercise regimens for Type 2 DM. However, the importance of these regimens in the treatment of Type 2 DM cannot be minimized because they have the potential to promote weight loss and improve insulin sensitivity.
ISSUES RELATED TO TYPE 2 OM IN THE WORKPLACE
Type 2 DM is likely to become a more prominent issue in the workplace setting. It is important to recognize this disorder is occurring at younger ages, as noted in the previous scenarios. As a result, it is likely the numbers of individuals with Type 2 DM in the workplace will increase. Therefore, the role of the occupational health nurse in the prevention and the treatment of this disorder is essential. The prevention of DM among employees remains a goal for all workplace settings. Programs geared toward improving diet and increasing physical activity will help with the dual purpose of treating DM in individuals affected and preventing DM in individuals at risk.
To prevent the development of complications, clients need to take an active approach to managing their blood glucose, blood pressure, and lipids. The ability to monitor blood glucose levels in the workplace is essential in both tracking blood glucose levels and assessing for hypoglycemia. Clients with Type 2 DM need to work with the occupational health nurse to explore the causes of problems such as sustained hyperglycemia and frequent hypoglycemia. In addition, clients need to understand the need for preventive treatments (e.g., flu shots) in caring for this chronic disease.
As noted previously, a variety of medications for the treatment of Type 2 DM have been introduced to the U.S. market during a short period of time. With more complex regimens, client~ may require 7 to 12 or more diabetes pills per day. Clients need help planning the best times to administer their medications, particularly those taken with meals (e.g., aglucosidase inhibitors). Shift work presents a variety of challenges to individuals, particularly when those clients use insulin. A detailed examination of mealtimes and snacks in both the workplace and home is necessary to provide appropriate medication or insulin coverage.
SUMMARY
Type 2 DM is occurring at earlier ages in epidemic proportions, thereby increasing the number of individuals with T}'pe 2 DM in the workplace. Health care providers, especially occupational health nurses, have an opportunity to effect Clinical Rounds: NP Link change in the trajectory of complications associated with DM by promoting optimal DM management in the workplace.
